IL6 and cancer: Moreover, therapeutic targeting of NCL also stimulated the tumor-infiltrated T lymphocytes, impaired cancer-associated fibroblast, and reprogrammed the tumor microenvironment via suppression of interleukin-6 in PanCa [57].